Galapagos (GLPG) Stock Price, News & Analysis

Company Overview

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development. Its lead asset, filgotinib—a selective JAK1 inhibitor—was developed in collaboration with Gilead Sciences for the treatment of rheumatoid arthritis, ankylosing spondylitis and inflammatory bowel disease. In addition to filgotinib, Galapagos is advancing compounds targeting osteoarthritis, idiopathic pulmonary fibrosis and APOL1-mediated kidney disease, with several candidates currently in Phase 2 and Phase 3 clinical trials.

Galapagos maintains strategic partnerships and licensing agreements to extend its research capabilities and global reach. In 2019, the company entered into a collaboration and license agreement with Gilead Sciences, which included an equity investment and options on select pipeline programs. Galapagos also collaborates with Servier, a French pharmaceutical company, to co-develop and commercialize multiple anti-inflammatory programs in Europe and other territories. Its clinical study sites and research facilities span Europe and the United States, reflecting a commitment to conducting trials and manufacturing operations in key markets.

Leadership at Galapagos is headed by Chief Executive Officer Paul Stoffels, who joined the company in 2020 after serving as Chief Scientific Officer at Johnson & Johnson. Under Stoffels’ direction, Galapagos has emphasized precision medicine and accelerated development timelines. The company employs a multidisciplinary team of scientists, clinicians and regulatory specialists, reinforcing its mission to translate genetic insights into first-in-class and best-in-class therapies for patients worldwide.

Key Stats

• Today's Range: $33.61 to $34.17
• 50-Day Range: $30.25 to $34.14
• 52-Week Range: $22.36 to $34.17
• Volume: 79,031 shs
• Average Volume: 159,157 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $26.00
• Consensus Rating: Strong Sell

Galapagos Stock Analysis - MarketRank™

Galapagos scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.8 / 5
• Analyst Rating: Strong Sell

Consensus Rating

Galapagos has received a consensus rating of Strong Sell. The company's average rating score is 1.17, and is based on no buy ratings, 1 hold rating, and 5 sell ratings.

Downside Risk

Galapagos has a consensus price target of $26.00, representing about 22.8% downside from its current price of $33.69.

Amount of Analyst Coverage

Galapagos has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Galapagos are expected to decrease in the coming year, from ($1.60) to ($3.11) per share.

Price to Book Value per Share Ratio

Galapagos has a P/B Ratio of 0.71. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.27% of the float of Galapagos has been sold short.

Short Interest Ratio / Days to Cover

Galapagos has a short interest ratio ("days to cover") of 5.5.

Change versus previous month

Short interest in Galapagos has recently decreased by 4.17%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Galapagos does not currently pay a dividend.

Dividend Growth

Galapagos does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.27% of the float of Galapagos has been sold short.

Short Interest Ratio / Days to Cover

Galapagos has a short interest ratio ("days to cover") of 5.5.

Change versus previous month

Short interest in Galapagos has recently decreased by 4.17%, indicating that investor sentiment is improving.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Galapagos insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.91% of the stock of Galapagos is held by insiders.

Percentage Held by Institutions

Only 32.46% of the stock of Galapagos is held by institutions.

GLPG Stock Analysis - Frequently Asked Questions

How have GLPG shares performed this year?

Galapagos' stock was trading at $27.50 at the beginning of 2025. Since then, GLPG stock has increased by 22.5% and is now trading at $33.69.

How were Galapagos' earnings last quarter?

Galapagos NV (NASDAQ:GLPG) issued its earnings results on Wednesday, April, 23rd. The biotechnology company reported ($2.47) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.23) by $2.24. The biotechnology company earned $97.33 million during the quarter, compared to analysts' expectations of $72.22 million.
Read the conference call transcript.

When did Galapagos IPO?

Galapagos (GLPG) raised $161 million in an initial public offering (IPO) on Thursday, May 14th 2015. The company issued 3,800,000 shares at $42.43 per share. Morgan Stanley, Credit Suisse and Cowen and Company served as the underwriters for the IPO and Nomura and Bryan, Garnier were co-managers.

Who are Galapagos' major shareholders?

Galapagos' top institutional investors include EcoR1 Capital LLC, Segall Bryant & Hamill LLC, Caption Management LLC and Primecap Management Co. CA.

How do I buy shares of Galapagos?

Shares of GLPG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Galapagos own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Galapagos investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY).

Company Calendar

• Last Earnings: 4/23/2025
• Today: 9/22/2025
• Next Earnings (Estimated): 10/22/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GLPG
• CIK: 1421876
• Web: www.glpg.com
• Phone: (321) 534-2900
• Fax: 321-534-2901
• Employees: 1,310
• Year Founded: 1999

Price Target and Rating

• Average Price Target for Galapagos: $26.00
• High Price Target: $30.00
• Low Price Target: $22.00
• Potential Upside/Downside: -23.3%
• Consensus Rating: Strong Sell
• Rating Score (0-4): 1.17
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.08
• Quick Ratio: 7.99

Sales & Book Value

• Annual Sales: $298.31 million
• Price / Sales: N/A
• Cash Flow: $0.72 per share
• Price / Cash Flow: 47.02
• Book Value: $47.57 per share
• Price / Book: 0.71

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Optionable
• Beta: 0.22